-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322

Benzinga·08/26/2026 16:24:13
Listen to the news
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $283 to $322.